Search

Your search keyword '"Rajpal, Rajesh K."' showing total 8 results
Start Over Author "Rajpal, Rajesh K." Publication Year Range Last 10 years
8 results on '"Rajpal, Rajesh K."'

3. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment

Author

Milner, Mark S., Beckman, Kenneth A., Luchs, Jodi I., Allen, Quentin B., Awdeh, Richard M., Berdahl, John, Boland, Thomas S., Buznego, Carlos, Gira, Joseph P., Goldberg, Damien F., Goldman, David, Goyal, Raj K., Jackson, Mitchell A., Katz, James, Kim, Terry, Majmudar, Parag A., Malhotra, Ranjan P., McDonald, Marguerite B., Rajpal, Rajesh K., Raviv, Tal, Rowen, Sheri, Shamie, Neda, Solomon, Jonathan D., Stonecipher, Karl, Tauber, Shachar, Trattler, William, Walter, Keith A., Waring, George O., IV, Weinstock, Robert J., Wiley, William F., and Yeu, Elizabeth

Published
2017
Full Text
View/download PDF

4. Addendum

Author

Hersh, Peter S., primary, Stulting, R. Doyle, additional, Muller, David, additional, Durrie, Daniel S., additional, and Rajpal, Rajesh K., additional

Published
2018
Full Text
View/download PDF

5. U.S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery

Author

Hersh, Peter S., primary, Stulting, R. Doyle, additional, Muller, David, additional, Durrie, Daniel S., additional, Rajpal, Rajesh K., additional, Binder, Perry S., additional, Donnenfeld, Eric D., additional, Durrie, Daniel, additional, Hardten, David, additional, Hersh, Peter, additional, Price, Francis, additional, Randleman, J. Bradley, additional, Schanzlin, David, additional, Stark, Walter, additional, Trattler, William, additional, and Trokel, Steven, additional

Published
2017
Full Text
View/download PDF

6. United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment

Author

Hersh, Peter S., primary, Stulting, R. Doyle, additional, Muller, David, additional, Durrie, Daniel S., additional, Rajpal, Rajesh K., additional, Binder, Perry S., additional, Donnenfeld, Eric D., additional, Durrie, Daniel, additional, Hardten, David, additional, Hersh, Peter, additional, Price, Francis, additional, Schanzlin, David, additional, Stark, Walter, additional, Trattler, William, additional, and Trokel, Steven, additional

Published
2017
Full Text
View/download PDF

7. Dysfunctional tear syndrome

Author

Milner, Mark S., primary, Beckman, Kenneth A., additional, Luchs, Jodi I., additional, Allen, Quentin B., additional, Awdeh, Richard M., additional, Berdahl, John, additional, Boland, Thomas S., additional, Buznego, Carlos, additional, Gira, Joseph P., additional, Goldberg, Damien F., additional, Goldman, David, additional, Goyal, Raj K., additional, Jackson, Mitchell A., additional, Katz, James, additional, Kim, Terry, additional, Majmudar, Parag A., additional, Malhotra, Ranjan P., additional, McDonald, Marguerite B., additional, Rajpal, Rajesh K., additional, Raviv, Tal, additional, Rowen, Sheri, additional, Shamie, Neda, additional, Solomon, Jonathan D., additional, Stonecipher, Karl, additional, Tauber, Shachar, additional, Trattler, William, additional, Walter, Keith A., additional, Waring, George O., additional, Weinstock, Robert J., additional, Wiley, William F., additional, and Yeu, Elizabeth, additional

Published
2017
Full Text
View/download PDF

8. Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain.

Author

Salinger CL, Gaynes BI, and Rajpal RK

Subjects
Administration, Topical, Adult, Aged, Aged, 80 and over, Eye Diseases epidemiology, Female, Humans, Male, Middle Aged, Ophthalmic Solutions administration & dosage, United States, Anti-Allergic Agents administration & dosage, Eye Diseases complications, Eye Diseases surgery, Eye Pain drug therapy, Inflammation drug therapy, Loteprednol Etabonate administration & dosage, Postoperative Complications drug therapy
Abstract

Topical ophthalmic corticosteroids are of clinical benefit in the management of pain and inflammation after ocular surgery; however, their use can be associated with class-associated adverse events (AEs) and limited bioavailability. Selection of an appropriate topical corticosteroid depends on drug-specific variables such as AE profile, efficacy, potency, dosing, patient-specific administration needs, and formulation properties aimed at minimizing precorneal drug loss, increasing ocular surface drug residence time, and maximizing drug delivery to the anterior tissues. Recently, strategies for improving ocular penetration of ophthalmic formulations have included use of mucoadhesive formulations (ie, polycarbophil-containing gels) and drug particle size reduction, enabling faster drug dissolution and therefore increased bioavailability and penetration. Loteprednol etabonate (LE) is a carbon-20 ester corticosteroid developed through retrometabolic drug design with potent anti-inflammatory effects and a reduced propensity for eliciting corticosteroid class AEs. This drug has been formulated for topical ophthalmic use after surgery as 0.5% and 1% suspensions, a 0.5% ointment, and a 0.5% gel. Preclinical and clinical data for a new 0.38% LE gel will be reviewed demonstrating that reducing the drug particle size to the nanometer range in diameter provides effective ocular tissue penetration and resolution of pain and inflammation despite a reduced drug concentration (0.38%) and dosing frequency.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results